Doro Altan Anna Maria, Majid Noorjehan, Orlando Stefano, Uamusse Elton, Rafael Marcia, Sidumo Zita, Guidotti Giovanni, Ciccacci Fausto
DREAM Program, Community of Sant'Egidio, Rome, Italy.
Link Campus University, Rome, Italy.
AIDS Res Ther. 2025 Jan 30;22(1):8. doi: 10.1186/s12981-025-00708-w.
The global HIV epidemic remains a major public health challenge, with DTG playing a key role in ART regimens due to its efficacy and tolerability. This study evaluated virological outcomes and resistance mutations in patients on DTG in Mozambique through a retrospective cohort study in seven DREAM centers. Data from 29,601 patients (98.1% on DTG) revealed a virological suppression rate of 95% (27,622/29,051). Factors positively associated with suppression included age > 50, longer ART duration, and being female. Of 17 resistance tests, 8 showed major mutations, including G118R and E138K. Results highlight DTG's effectiveness and the need for resistance surveillance.
全球艾滋病病毒流行仍然是一项重大的公共卫生挑战，由于其有效性和耐受性，多替拉韦（DTG）在抗逆转录病毒治疗（ART）方案中发挥着关键作用。本研究通过对莫桑比克7个DREAM中心进行回顾性队列研究，评估了接受DTG治疗的患者的病毒学结果和耐药突变情况。来自29601名患者的数据（98.1%接受DTG治疗）显示病毒学抑制率为95%（27622/29051）。与抑制呈正相关的因素包括年龄>50岁、ART疗程较长以及女性。在17次耐药检测中，8次显示有主要突变，包括G118R和E138K。结果突出了DTG的有效性以及耐药监测的必要性。
